Fractyl Health (GUTS)
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System...
- Open
- 0.8050
- High
- 0.8090
- Low
- 0.7528
- Prev. Close
- 0.7800
- Volume
- 466.42K
- Turnover
- 363.15K
- Avg Price
- 0.7786
- Bid/Ask Ratio
- 80.72%
- Amplitude
- 7.21%
- 52wk High
- 2.4450
- Volume Ratio
- 1.68
- Turnover Ratio
- 0.32%
Fractyl Health Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$5.03560.54%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy0.00%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 1 day ago, 07:26 PM
Fractyl Health Earnings Call Signals Promise Amid Risks
- MorningStar · 2 days ago, 08:00 PM
Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action
- PUBT · Aug 20 at 06:18 AM
Fractyl Health spotlights REMAIN-1 data showing Revita maintains 84% of GLP-1 weight loss in optimized cohort
- PUBT · Aug 20 at 06:04 AM
Fractyl Health to host virtual Commercial Strategy Day on Revita go-to-market plan
- PUBT · Aug 14 at 03:17 PM
Fractyl Health announces special stockholder meeting
- Market Beat · Aug 14 at 04:04 AM
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial
